Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Daniel D. De Carvalho"'
Publikováno v:
Cancer Discovery. 11:2707-2725
Features of the cancer epigenome distinguish cancers from their respective cell of origin and establish therapeutic vulnerabilities that can be exploited through pharmacologic inhibition of DNA- or histone-modifying enzymes. Epigenetic therapies conv
Autor:
Thomas Kislinger, Jeffrey Zuccato, Shahbaz Khan, Yasin Mamatjan, Sébastien Froelich, Gelareh Zadeh, Namita Sinha, Shirin Karimi, Olivia Singh, Jeffrey C Liu, Ankur Chakravarthy, Anne-Laure Bernat, Joao Paulo Almeida, Homa Adle-Biassette, Farshad Nassiri, Sheila Mansouri, Vikas Patil, Kenneth Aldape, Mohammed Hasen, Daniel D. De Carvalho
Publikováno v:
Neuro Oncol
Background Chordomas are rare malignant bone cancers of the skull-base and spine. Patient survival is variable and not reliably predicted using clinical factors or molecular features. This study identifies prognostic epigenetic chordoma subtypes that
Autor:
Shengrui Feng, Daniel D. De Carvalho
Publikováno v:
The FEBS Journal. 289:1214-1239
The appropriate coordination between epigenetic regulators is essential for spatial and temporal regulation of gene expression and maintenance of cell identity. Cancer is a disease driven by both genetic and epigenetic alterations. The widespread dys
Autor:
Wail Ba-alawi, Evelyne Lima-Fernandes, Jason W. Locasale, Daniel D. De Carvalho, Paul Savage, Ilias Ettayebi, Hellen Kuasne, Morag Park, Felicia Tai, Yunchi Ingrid Kao, Benjamin Haibe-Kains, Alexandra N. Fedor, Paul Guilhamon, Giacomo Grillo, Seyed Ali Madani Tonekaboni, Cheryl H. Arrowsmith, Xiaojing Liu, Constanza Martinez, Anne-Marie Fortier, Mathieu Lupien, Alex Murison, Geneviève Deblois, David W. Cescon
Publikováno v:
Cancer Discovery. 10:1312-1329
Tumor progression upon treatment arises from preexisting resistant cancer cells and/or adaptation of persister cancer cells committing to an expansion phase. Here, we show that evasion from viral mimicry response allows the growth of taxane-resistant
Autor:
Karan J. Abraham, Miling Wang, Jack Greenblatt, Lauren A. Ostrowski, Aparna Gorthi, Parasvi S. Patel, Daniel D. De Carvalho, Razq Hakem, Michael Ohh, Roxanne Oshidari, Alexander J.R. Bishop, Violena Pietrobon, Anas Samman, Arash Algouneh, Dorothy Yanling Zhao, Stephen Lee, Michael Bokros, Janet N.Y. Chan, V Talya Yerlici, Rajat Singhania, Brendan C. Dickson, Yupeng Liu, Elva Vidya, Negin Khosraviani, Karim Mekhail
Publikováno v:
Nature
Proteins are manufactured by ribosomes—macromolecular complexes of protein and RNA molecules that are assembled within major nuclear compartments called nucleoli1,2. Existing models suggest that RNA polymerases I and III (Pol I and Pol III) are the
Publikováno v:
Clin Cancer Res
PURPOSE. Ovarian cancer is a heterogeneous disease that can be divided into multiple subtypes with variable etiology, pathogenesis, and prognosis. We analyzed DNA methylation profiling data to identify biologic subgroups of ovarian cancer and study t
Publikováno v:
Nature Reviews Cancer. 19:151-161
DNA methylation inhibitors have become the mainstay for treatment of certain haematological malignancies. In addition to their abilities to reactivate genes, including tumour suppressors, that have acquired DNA methylation during carcinogenesis, they
Publikováno v:
Trends in Cell Biology. 29:31-43
During cancer initiation and progression, the somatic epigenome is broadly reprogrammed. This reprogramming can be a consequence of several processes, including altered transcriptional profiles and mutations. In addition, immune cells infiltrating th
Autor:
Bo Zhang, Yasheng Zhu, Xiaojie Bian, Mingyao Liu, Daniel D. De Carvalho, Chao Wang, Zhengfang Yi, Yu-Tian Xiao, Song Wu, Housheng Hansen He, Fraser Soares, Paul C. Boutros, Theodorus H. van der Kwast, Zhou Jiang, Ke-Qin Dong, Javier Mariscal, Jianhua Wang, Helen Loo Yau, Alejandro Berlin, Guanghui Zhu, Qinghua Guo, Weidong Chen, Fubo Wang, Shancheng Ren, Yongwei Yu, Yue Yang, Dolores Di Vizio, Na Zhang, Michael Fraser, Fei Liu, Dai Chen, Yin Liu, Sujun Chen
Publikováno v:
Nature cell biology. 23(1)
Prostate cancer shows remarkable clinical heterogeneity, which manifests in spatial and clonal genomic diversity. By contrast, the transcriptomic heterogeneity of prostate tumours is poorly understood. Here we have profiled the transcriptomes of 36,4
Publikováno v:
Clin Cancer Res
PURPOSE: The current paradigm in the development of high-grade serous ovarian carcinoma (HGSC) proposes that the majority of HGSCs arise from precursor serous tubal intraepithelial carcinoma (STIC) lesions of the fallopian tube. Here we survey genome